Literature DB >> 20013075

Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Joana A Carvalho1, Adriano R Azzoni, Duarte M F Prazeres, Gabriel A Monteiro.   

Abstract

Plasmid vectors can be optimized by including specific signals that promote antigen targeting to the major antigen presentation and processing pathways, increasing the immunogenicity and potency of DNA vaccines. A pVAX1-based backbone was used to encode the Green Fluorescence Protein (GFP) reporter gene fused either to ISG (Invariant Surface Glycoprotein) or to TSA (trans-sialidase) Trypanosoma brucei genes. The plasmids were further engineered to carry antigen-targeting sequences, which promote protein transport to the extracellular space (secretion signal), lysosomes (LAMP-1) and to the endoplasmic reticulum (adenovirus e1a). Transfection efficiency was not affected by differences in the size between each construct as no differences in the plasmid copy number per cell were found. This finding also suggests that the addition of both ISG gene and targeting sequences did not add sensitive regions prone to nuclease attack to the plasmid. Cells transfected with pVAX1GFP had a significant higher number of transcripts. This could be a result of lower mRNA stability and/or a lower transcription rate associated with the bigger transcripts. On the other hand, no differences were found between transcript levels of each ISG-GFP plasmids. Therefore, the addition of these targeting sequences does not affect the maturation/stability of the transcripts. Microscopy analysis showed differences in protein localization and fluorescent levels of cells transfected with pVAX1GFP and ISG constructs. Moreover, cells transfected with the lamp and secretory sequences presented a distinct distribution pattern when compared with ISG protein. Protein expression was quantified by flow cytometry. Higher cell fluorescence was observed in cells expressing the cytoplasmic fusion protein (ISG-GFP or TSA-GFP) compared with cells where the protein was transported to the lysosomal pathway. Protein transport to the endoplasmic reticulum does not lead to a decrease in the mean fluorescence values. The secretion signal was only effective when used in conjunction with TSA gene. Therefore, the characteristics of each protein (e.g., presence of transmembrane domains) might influence the efficacy of its cellular transport. This analysis constitutes a useful tool for the optimization of the design of DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013075     DOI: 10.1007/s12033-009-9229-x

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  49 in total

1.  Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes.

Authors:  A Krogh; B Larsson; G von Heijne; E L Sonnhammer
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

2.  Quantitative analysis of correlation between number of nuclear plasmids and gene expression activity after transfection with cationic liposomes.

Authors:  Rieko Tachibana; Hideyoshi Harashima; Naoko Ide; Sachiko Ukitsu; Yasuko Ohta; Norio Suzuki; Hiroshi Kikuchi; Yasuo Shinohara; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

3.  The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression.

Authors:  Adriano R Azzoni; Sofia C Ribeiro; Gabriel A Monteiro; Duarte M F Prazeres
Journal:  J Gene Med       Date:  2007-05       Impact factor: 4.565

4.  The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway.

Authors:  A L Ruff; F G Guarnieri; K Staveley-O'Carroll; R F Siliciano; J T August
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

5.  Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization.

Authors:  J S Boyle; C Koniaras; A M Lew
Journal:  Int Immunol       Date:  1997-12       Impact factor: 4.823

6.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.

Authors:  Gillis R Otten; Mary Schaefer; Barbara Doe; Hong Liu; Indresh Srivastava; Jan zur Megede; Jina Kazzaz; Ying Lian; Manmohan Singh; Mildred Ugozzoli; David Montefiori; Mark Lewis; David A Driver; Thomas Dubensky; John M Polo; John Donnelly; Derek T O'Hagan; Susan Barnett; Jeffrey B Ulmer
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

Authors:  Daqing Wang; Mary E Christopher; Les P Nagata; Monika A Zabielski; Hongduo Li; Jonathan P Wong; John Samuel
Journal:  J Clin Virol       Date:  2004-12       Impact factor: 3.168

9.  Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.

Authors:  Ying-Kit Cheung; Samuel Chak-Sum Cheng; Fion Wan-Yee Sin; Yong Xie
Journal:  Vaccine       Date:  2004-12-16       Impact factor: 3.641

10.  Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

Authors:  Rong Xu; Shakuntala Megati; Vidia Roopchand; Amara Luckay; Amjed Masood; Dorys Garcia-Hand; Margherita Rosati; David B Weiner; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; John H Eldridge; Michael A Egan
Journal:  Vaccine       Date:  2008-07-25       Impact factor: 4.169

View more
  1 in total

Review 1.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.